Observational studyBritish journal of clinical pharmacology2026
Linezolid-induced lactic acidosis in critically ill patients: A multicentre study of incidence, severity and predictors.
Observational study in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Linezolid-induced lactic acidosis in critically ill patients: A multicentre study of incidence, severity and predictors.British journal of clinical pharmacology · 2026Observational
- Severe co-infection with influenza A virus H3N2 and community-acquired methicillin-susceptibleFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLinezolid, a synthetic oxazolidinone for resistant gram-positive infections, is generally associated with mild adverse effects such as gastrointestinal disturbances, but more serious reactions like lactic acidosis (LA) have also been reported. LA may be more pronounced in critically ill patients; therefore, this study aims to determine the incidence, severity and predictors of linezolid-associated LA in this vulnerable population.
methodsWe conducted a retrospective observational study of adult ICU patients receiving linezolid from January 2021 to May 2025. Data on demographics, comorbidities, linezolid regimen, concomitant medications and laboratory values were collected. Multivariate logistic regression was used to identify predictors of LA.
resultsOf 904 patients screened, 551 were included (mean age 56 years; 73.3% male). LA occurred in 10.7% (n = 59) and was classified as moderate (22%), severe (49%) or critical (29%), with a mean onset of 4 days. Independent predictors of LA included linezolid at a daily dose of 600 mg (aOR = 50.4; p = 0.028), sepsis (aOR = 2.61; p = 0.042), infections other than pneumonia (aOR = 4.0; p = 0.042) and the use of norepinephrine (aOR = 3.56; p = 0.005).
conclusionLinezolid-associated lactic acidosis is a frequent and often severe complication in ICU patients, typically developing early during therapy. Sepsis, non-pneumonia infections and norepinephrine use were identified as key risk factors. These findings highlight the need for early recognition and vigilant monitoring of high-risk patients to promote safer use of linezolid in critically ill populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.